Results 21 to 30 of about 61,476 (246)

Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer

open access: yes, 2022
Pancreatic ductal adenocarcinoma (PDAC) is a component of familial melanoma due to germline pathogenic variants (GPVs) in CDKN2A. However, it is unclear what role this gene or other genes play in its etiology.PURPOSE Pancreatic ductal adenocarcinoma ...
Stefania Sciallero   +37 more
core   +1 more source

Impact of PCSK9, WDR12, CDKN2A, and CXCL12 Polymorphisms in Jordanian Cardiovascular Patients on Warfarin Responsiveness and Sensitivity

open access: yesInternational Journal of General Medicine, 2021
Rasheed K Ibdah,1 Laith N AL-Eitan,2 Nasr N Alrabadi,3 Ayah Y Almasri,2 Adan H Alnaamneh,2 Rame H Khasawneh,4 Mansour A Alghamdi5,6 1Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology,
Ibdah RK   +6 more
doaj  

Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma [PDF]

open access: yes, 2017
Background Sarcomas are rare mesenchymal malignancies whose pathogenesis is poorly understood; both environmental and genetic risk factors could contribute to their aetiology.
Koscielny, Serge   +150 more
core   +1 more source

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer

open access: yesCancer Management and Research, 2021
Danijel Sikic,1,2 Helge Taubert,1,2 Johannes Breyer,3 Markus Eckstein,2,4 Veronika Weyerer,2,4 Bastian Keck,1,2 Jennifer Kubon,1,2 Wolfgang Otto,3 Thomas S Worst,5 Maximilian C Kriegmair,5 Philipp Erben,5 Arndt Hartmann,2,4 Bernd Wullich,1,2 Ralph M ...
Sikic D   +14 more
doaj  

Childhood Acute B-Lineage Lymphoblastic Leukemia With CDKN2A/B Deletion Is a Distinct Entity With Adverse Genetic Features and Poor Clinical Outcomes

open access: yesFrontiers in Oncology, 2022
To further emphasize the clinical–genetic features and prognosis of CDKN2A/B deletions in childhood acute lymphoblastic leukemia (ALL), we retrospectively analyzed 819 consecutive B-ALL patients treated with the Chinese Children’s Cancer Group ALL-2015 ...
Jing Feng   +8 more
doaj   +1 more source

Effects of CDKN2A (p16INK4A/p14ARF) Over-Expression on Proliferation and Migration of Human Melanoma A375 Cells

open access: yesCellular Physiology and Biochemistry, 2016
Objective: This study aims to investigate the effects of CDKN2A (p16INK4A/p14ARF) over-expression on the proliferation and migration of human melanoma A375 cells. Methods: Melanoma tissues and pigmented nevi tissues were collected.
Ming Bai   +4 more
doaj   +1 more source

Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas [PDF]

open access: yes, 2011
Background CDKN2A-mutation carriers run a high risk of developing melanomas and have an increased risk of developing pancreatic cancer (PC). Familial PC (FPC) patients with a personal history or family history of melanomas are therefore offered CDKN2A ...
Rolf H. Sijmons   +57 more
core   +1 more source

Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance

open access: yeseLife, 2022
Pathogenic germline CDKN2A variants are associated with an increased risk of pancreatic ductal adenocarcinoma (PDAC). CDKN2A variants of uncertain significance (VUSs) are reported in up to 4.3% of patients with PDAC and result in significant uncertainty ...
Hirokazu Kimura   +9 more
doaj   +1 more source

Prognostic Effect of CDKN2A Homozygous Deletion and Beclin 1 in Isocitrate Dehydrogenase Mutant Glial Tumors

open access: yesNeurological Sciences and Neurophysiology
Background: In the updated World Health Organization Classification of Central Nervous System Tumors, the presence of CDKN2A/2B homozygous deletion is now recognized as the indicative of Grade 4 in isocitrate dehydrogenase (IDH) mutant astrocytomas, and ...
Ganime Çoban   +6 more
doaj   +1 more source

Association between early risk factors and CDKN2A/B deletion in pediatric patients with acute lymphoblastic leukemia in a pediatric cancer center in Colombia

open access: yesPediatric Hematology Oncology Journal, 2022
Cyclin dependent kinase inhibitor (CDKN) 2A/B deletion is correlated with poor risk factors, such as high blood cell count, higher rate of induction therapy failure, and earlier relapses in pediatric patients with acute lymphoblastic leukemia (ALL).
Cindy Martinez   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy